Sunscreen Ingredient Absorption: What Systemic Detection Means

Finding a sunscreen ingredient in blood answers one question: some amount crossed the skin and entered systemic circulation under the study conditions, but it does not answer whether that amount causes harm, whether ordinary use produces the same concentration, or whether the risks of use exceed the known risks from ultraviolet radiation.

Two randomized trials led by FDA researchers were designed to measure absorption under maximal-use conditions, and their results changed the evidence conversation by showing that several active ingredients exceeded an FDA threshold used to decide when additional toxicology data are needed. Headlines often turned that testing trigger into a safety alarm. The distinction is central.

Why regulators ask about systemic absorption#

Topical use does not guarantee that an ingredient stays only on the surface. Skin condition, body area, formulation, frequency, duration, temperature, and the ingredient's chemistry can affect how much reaches circulation. A blood concentration can therefore inform which safety studies are needed.

FDA maximal-usage trial guidance describes a pharmacokinetic study performed under conditions intended to produce the greatest likely systemic absorption consistent with the proposed use. The design is a stress test. It helps avoid falsely concluding that systemic availability is negligible because a study used unusually limited conditions.

The output is a concentration-time profile: how soon the ingredient is measurable, how high the concentration becomes, whether it accumulates, and how long it remains detectable; those data can guide toxicology and clinical-safety requirements.

Pharmacokinetics is not toxicology. Detection says that systemic study may be relevant. Toxicology asks what biological effects occur at specified amounts and durations. Clinical studies ask what outcomes occur in people. Each layer addresses a different question.

The 2019 trial#

The 2019 JAMA trial enrolled 24 healthy adults and randomized six participants to each of four sunscreen formulations. The protocol represented maximal use over most of the body during four days in a clinical research unit. It tested four active ingredients across the formulations: avobenzone, oxybenzone, octocrylene, and ecamsule.

All four ingredients reached blood concentrations above 0.5 ng/mL under the study conditions. Several were measurable after the first study day, and some remained detectable after use ended. The exact concentrations varied by ingredient and formulation.

The study was small and described by its authors as a preliminary maximal-usage trial. Six participants per formulation were enough to show that the threshold was crossed, not to characterize absorption across the full diversity of users, skin conditions, ages, climates, and real-world behaviors. The authors' conclusion was not that the ingredients caused harm. It was that systemic absorption supported further study to determine clinical significance.

The 2020 trial#

The 2020 JAMA trial expanded the design to 48 healthy adults and four formulations. It measured six active ingredients: avobenzone, oxybenzone, octocrylene, homosalate, octisalate, and octinoxate.

Under maximal-use conditions, all six had geometric mean maximum blood concentrations above 0.5 ng/mL. Concentrations for several ingredients exceeded the threshold after the first day, and some ingredients remained detectable well after the application period.

The study confirmed that the 2019 finding was not limited to the first four formulations. It also supplied more detailed pharmacokinetic information. It still did not compare disease outcomes, measure decades of use, or establish a concentration at which human harm begins.

Short-term adverse events recorded during a pharmacokinetic study cannot settle uncommon or long-latency safety questions. Conversely, the absence of a clinical-outcome design does not make the measured absorption unimportant. It means the next evidence question is toxicologic and clinical significance.

What 0.5 ng/mL means#

The FDA threshold comes from a toxicological-screening concept used to decide when systemic carcinogenicity and developmental or reproductive studies may be needed for a topically applied ingredient; it is intentionally conservative as a testing trigger.

It is not a known-effect concentration for any one sunscreen ingredient. Crossing it does not show that harm occurred, and staying below it does not certify safety under every circumstance. The number organizes the evidence required for regulatory review.

This is a common source of category error. A headline may say an ingredient was found at "more than the FDA limit." Readers can reasonably infer a legal or toxicity limit. In these trials, the comparison was to a threshold for additional assessment, not a maximum permitted blood concentration or a demonstrated harm boundary.

The relevant questions after detection are ingredient-specific. What are the peak and cumulative concentrations? How do they compare with amounts in nonclinical and human safety data? Are metabolites important? What happens with long duration, vulnerable populations, or altered skin? Do any observed biological changes translate into clinical outcomes?

Why maximal use is both a strength and a limit#

The design's strength is sensitivity. If a study used a small skin area for a short period, it could miss systemic absorption that occurs under labeled high-use conditions. Maximal use gives regulators a stronger basis for deciding which safety data are needed.

Its limit is direct generalization. Many people will not reproduce the study's body area, controlled schedule, duration, formulation, or environment. Others may use sunscreen over long periods, on altered skin, or in conditions not represented by healthy adult volunteers.

It is therefore wrong to dismiss the trial as "unrealistic" and equally wrong to treat its concentration as everyone's ordinary level. The trial estimates a high-use pharmacokinetic condition. Real-world studies and formulation-specific data can address how that relates to usual patterns.

Formulation matters because active ingredients do not cross skin in isolation. The vehicle, other ingredients, skin preparation, and product characteristics can change absorption. One formulation's concentration cannot be assigned automatically to every formulation containing the same active ingredient.

Detection and demonstrated harm are different evidence claims#

Systemic detection is a measurement claim. Demonstrated harm requires evidence connecting a defined amount or use pattern to an adverse outcome with adequate control of bias and uncertainty.

Mechanistic or animal findings can identify hazards and guide study. Their relevance depends on species, route, amount, metabolism, endpoint, and margin relative to human concentrations. Observational human studies can address long-term outcomes but face confounding from health behavior, sun habits, skin type, and product selection. Randomized long-term harm trials may be impractical for rare outcomes.

Regulatory assessment therefore integrates pharmacokinetics, nonclinical studies, human studies, postmarket reports, and the benefits of ultraviolet protection. No single study design supplies every part.

The opposite error is also possible. Saying "no harm was proved" is not the same as showing long-term safety. The absorption trials identified missing evidence that regulators considered important. Uncertainty should be stated without turning it into either reassurance or alarm beyond the data.

The current US monograph framework#

The federal over-the-counter monograph system sets conditions under which qualifying nonprescription products can be marketed without a product-specific approved application, and the 2020 CARES Act moved this system from rulemaking to administrative orders.

For sunscreen, a deemed final order created by operation of law establishes the current monograph baseline. FDA's 2021 questions-and-answers page explains that it draws largely on the stayed 1999 monograph plus later labeling and testing requirements. Under that baseline, 16 legacy active ingredients are treated as generally recognized as safe and effective when all applicable conditions are met.

FDA also issued a broad proposed order in 2021 to revise that baseline. A proposal describes possible future requirements. It does not take effect until finalized. FDA stated again in 2026 that this broad proposed order had not yet been finalized and that its changes remained under review. That distinction is essential when you are dating a claim: the current legal baseline, the 2021 proposed scientific findings, and later ingredient-specific orders are related but not interchangeable.

What the 2021 proposed findings said#

The proposed order placed the 16 legacy ingredients into three groups. It proposed generally recognized as safe and effective status for zinc oxide and titanium dioxide. It proposed that PABA and trolamine salicylate were not generally recognized as safe and effective because of identified safety concerns.

For the other 12, FDA said additional data were needed to support a positive finding: cinoxate, dioxybenzone, ensulizole, homosalate, meradimate, octinoxate, octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, and avobenzone.

FDA explicitly stated that this insufficient-data category was not a conclusion that those ingredients were unsafe. "Not enough evidence for a positive GRASE determination" and "evidence demonstrates harm" are different regulatory findings. The proposed order itself did not require removal of products. Until a final revision or relevant ingredient-specific order takes effect, marketing under the monograph is governed by the current final requirements and other applicable law.

The June 2026 bemotrizinol order#

On June 9, 2026, FDA issued final administrative order OTC000039 to add bemotrizinol to the sunscreen monograph under specified conditions. The order states that FDA reviewed human clinical and nonclinical evidence and concluded that the ingredient is generally recognized as safe and effective under those conditions.

This was an ingredient-specific order, not finalization of the entire 2021 broad proposal. It should not be described as resolving the status of all legacy ingredients.

The order's legal timing also matters. It states an effective date of August 9, 2026, or a later date under the statutory process if the order is disputed. On this article's source-check date, July 15, 2026, the order had been issued but its scheduled effective date had not yet arrived. This article does not give you formulation, concentration, combination, or purchasing instructions; those conditions belong to the FDA order and compliant labeling, not to a general evidence explainer.

How FDA frames the public-health balance#

FDA states that sun safety is important across skin tones and that the request for more ingredient data should not be read as a reason to abandon sun protection. The agency places sunscreen within a broader strategy that also includes shade, protective clothing, hats, and sunglasses.

That position reflects two evidence questions at once. Ultraviolet radiation has established harms, while some ingredient questions require more long-term data. A rational response addresses both rather than acting as if only one exists. If you have had a skin reaction, have a specific medical condition, are pregnant, or are wondering about use in an infant or child, ask a qualified clinician; this article does not compare commercial products or recommend a formulation.

A framework for reading absorption headlines#

First work out what was actually measured. Blood concentration is not a clinical endpoint. A laboratory or hormonal signal is not automatically a disease outcome. A hazard finding is not a risk estimate without information about amount and conditions.

Next identify the study condition. Was it maximal use, ordinary observed behavior, a single formulation, or long-term follow-up? How many participants were studied, and were vulnerable groups represented?

Then interpret the comparator correctly. Was the concentration compared with an assay limit, a screening threshold for more testing, a nonclinical effect level, or a human harm threshold? These values have different meanings.

Finally, check regulatory status and date. A proposed order, deemed final order, ingredient-specific final order, and effective order are distinct. Do not let "insufficient data" become "unsafe" in your reading, and do not let "no demonstrated harm" become "fully proven safe." Calibrated interpretation leaves room for both established benefit and unresolved safety questions.

References#

1. JAMA 2019 maximal-use sunscreen absorption trial
2. JAMA 2020 randomized maximal-use sunscreen absorption trial
3. FDA maximal-usage trial guidance for topical active ingredients
4. FDA deemed final and proposed sunscreen order questions
5. FDA 2026 update on the unfinalized broad sunscreen proposal
6. FDA final administrative order OTC000039, issued June 2026
7. FDA sun protection and sunscreen information